News

The use of epi-on photorefractive intrastromal cross linking reduced myopia by about 0.25 D in a small study; In a high-oxygen group, the effect averaged 1.25 D.

Hyperopic SMILE is being investigated in a prospective study. Early outcomes show good efficacy, safety, and predictability along with some interesting differences compared with hyperopic LASIK.

Wavefront-guided LASIK and wavefront-guided PRK following previous keratorefractive surgery demonstrate similar safety, efficacy, and predictability and result in comparable wavefront outcomes.

Excimer laser treatments using vector planning resulted in less corneal astigmatism, less refractive cylinder, and better unaided visual acuity postoperatively than treatments using manifest refractive treatment parameters alone, according to Noel Alpins, MD.

See what eye exams may be composed of in a few years.

A new questionnaire can help assess candidates’ symptoms before LASIK surgery, monitor them for visual symptoms as well as satisfaction after LASIK surgery, and measure the impact any post-LASIK symptoms have on a patient’s ability to function.

Decentration of less than 0.75 mm from a light-constricted pupil with a novel corneal inlay for the surgical correction of presbyopia does not affect visual acuity, task performance, or severity of halos and glare.

Patients with a contact lens lost in the eye are not a rare occurrence for ophthalmologists. However, 27 lenses at the same time may be another story! Another ophthalmologist shares his experience with a case involving 5 lenses within a patient's eye.

Descemet’s stripping automated endothelial keratoplasty (DSAEK) appears to have a higher risk of postoperative fungal infections (predominantly Candida) when compared to penetrating keratoplasty (PK).

Presbyopia patients have changed. They are younger than ever, more active than ever before, and they have more treatment options than ever before.

'Teleglaucoma’ is feasible and can play a major role in blindness prevention. Telemedicine and teleglaucoma are going to be an important part of how physicians take care of patients in the United States and worldwide.

Aerie Pharmaceuticals is developing the first novel mechanism of action for the treatment of glaucoma in over 20 years. The company is developing two products for the treatment of patients with glaucoma and ocular hypertension. One is an entirely new agent, netarsudil, the other is a combination of netarsudil plus latanoprost.

Alcon Laboratories pharmaceutical products have been moved into the Novartis Pharmaceutical Division. The switch means a sharper focus on research and development in ophthalmology as well as better access to Norvartis’ patient services and support capabilities.

The pharma drought is coming to a close. After decades of same-old medications for glaucoma and ocular surface disease, a series of new agents with new mechanisms of action (MOA) are moving toward marketing approval.

Bausch + Lomb (B + L) is more than one of the oldest eye care companies in the industry. It is also one of the broadest, with portfolios in contact lenses, consumer eye products, cataract surgery, intraocular lenses, retina surgery, and a wide range of ophthalmic pharmaceutical products.

Glaucoma has an adherence problem. Drugs that are highly efficacious are far less than optimally effective because patients fail to take eye drops properly or don’t take them all. Novel drug-delivery technologies could improve adherence and outcomes.

Animal models are vital to glaucoma research. The problem is that no single animal model fully recapitulates the natural history of human glaucoma. A model that mimicked the progression and time line of human glaucoma would do little to speed drug discovery.

Shire, which built its experience in biotech agents, is taking a biotech approach to meeting unmet needs in both the anterior and poster segments of ophthalmology.

Minimally invasive glaucoma surgery (MIGS) is the latest development in the treatment of glaucoma. With two MIGS devices already approved in the United States, there are a variety of novel devices that have the potential to transform the treatment of glaucoma.

Robert Chang, MD, outlines how artificial intelligence might work in glaucoma.

Changes in both technology and the healthcare policy are presenting new challenges for glaucoma specialists. As the demand for eye care surges, ophthalmologists are struggling to keep up–despite the availability of better tools for diagnosis and treatment.

Micropulse transscleral cyclophotocoagulation with a diode laser is demonstrating promising efficacy with better safety and tolerability than traditional TSCPC.

Yvonne Ou, MD, gives patients advice about physical activity, body positions to avoid, leafy green vegetables, caffeine, and blood pressure treatment–as suggestions to help patients control their glaucoma progression.

Medical therapy for glaucoma is not becoming obsolete, but it is evolving away from conventional topical administration.

L. Jay Katz, MD. outlined the benefits of home IOP monitoring. These devices will offer a wealth of information that should lead to increased understanding of glaucoma and better patient care.

Eye surgeons should use intracameral antibiotics only in select situations; they should avoid aminoglycosides, and they should not use vancomycin as prophylaxis. Michael Jumper, MD, offered this perspective as part of an overview of antibiotics used in intraocular surgery during the Glaucoma Symposium at the 2017 Glaucoma 360 meeting.

All corticosteroids matter when it comes to the risk of an intraocular pressure (IOP) response, and that is an important point for ophthalmologists to remember because opportunities for corticosteroid exposure are growing.

Although the aim of glaucoma management is to maintain visual function, the role of the ophthalmologist does not end once a patient has lost useful vision. Robert L. Stamper, MD, discussed care for patients with end-stage glaucoma.